Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York City on Tuesday, May 17, 2022, starting at 8:30 a.m. ET. Royalty Pharma senior executives will present on the outlook for royalty funding in life sciences, the company's capital deployment opportunities and long-term growth targets. The meeting will include live question and answer sessions.

Royalty Pharma Announces Inaugural Investor Day

Royalty Pharma's (RPRX) CEO Pablo Legorreta on Q4 2021 Results - Earnings Call Transcript

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2021 and introduced 2022 Adjusted Cash Receipts( 1) (a non-GAAP financial measure) guidance.

Royalty Pharma Reports Q4 and Full Year 2021 Results

AbbVie

Bristol-Myers

Charter Communications

Kroger

Mastercard

Marsh & McLennan

Sirius XM Holdings Inc

Teva Pharmaceutical

Visa

Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.

10 Stocks Warren Buffett Is Selling

NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 2021 financial results on Tuesday, February 15, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to Announce Fourth-Quarter and Full-Year 2021 Financial Results on February 15, 2022

Royalty Pharma (RPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Royalty Pharma (RPRX) Surges 5.4%: Is This an Indication of Further Gains?

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments and the full-year 2021 outlook for Net cash provided by operating activities (a GAAP financial measure) and Adjusted Cash Receipts (a non-GAAP financial measure). Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates today as part of a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually at 8:15 a.m. Eastern Time.

Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference

NEW YORK and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv mecarbil and the further development of aficamten. In addition, Cytokinetics sold to Royalty Pharma royalties on future worldwide sales of aficamten.

Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company's quarterly dividend over the previous quarter's dividend.

Royalty Pharma Announces 12% Dividend Increase

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10

The founder-led business is a profitable, cash flow positive business that is trading at a slight discount now. Six quarters after its IPO, the company has demonstrated a strong record of meeting/beating analysts' revenue and earnings estimates.

Royalty Pharma: A Pharma-Like Company Without The Same Risks

American Express

Bank of New York Mellon

Chevron

Johnson & Johnson

Kraft Heinz

Coca-Cola

STORE Capital

U.S. Bancorp

Verizon

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 12/15/21 YCharts data. 28 of 43 current Berkshire-Hathaway-owned-stocks pay dividends. As of 12/15/21, the top ten ranged 2.39%-5.06% by annual-yield and ranged 28.94%-185.22% per broker-estimated price-target-upsides.

Buffett's December Dividend Dogs Display 4 Dandy Dynomutts

Amgen

CVS Health

Medical Properties Trust

Should investors consider these healthcare dividend stocks amid the current market volatility?

5 Top Healthcare Dividend Stocks To Watch Today

AbbVie and Royalty Pharma should be on every dividend investor's radar right now.

2 Warren Buffett Dividend Stocks to Buy Right Now

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.

Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

BioCryst Pharmaceuticals

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). The largest buyer of pharmaceutical royalties globally, Royalty Pharma has purchased royalties for $150 million upfront on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor.

BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

Mondelez

Procter & Gamble

This Buffett holdings list from Kiplinger first appeared 9/16/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 11/16/21 YCharts data. 28 of 43 current Berkshire Hathaway-owned stocks pay dividends. As of 11/16/21 the top-ten ranged 2.36%-4.92% by annual yield and ranged 18.73%-87.33% per broker-estimated price-target-upsides.

3 Ideal Dogs Delight Buffett's November Dividend Holdings

Floor & Decor Holdings

Merck

Organon & Co

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes during the three months to the end of September.

Buffett Continues to Sell Stock as Turnover Increases

Liberty Global Ltd

Liberty Media Corp-Liberty SiriusXM

Berkshire Hathaway CEO Warren Buffett kept up his bearish streak in Q3 2021, but he did add a pair of positions from two of his favored industries.

10 Stocks Warren Buffett Is Selling (And 4 He's Buying)

Warren Buffett (Trades, Portfolio)'s multibillion-dollar conglomerate, Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial), disclosed its equity portfolio for the third quarter of 2021 on Monday.

Warren Buffett Buys 2 Stocks, Adds to Chevron Stake in 3rd Quarter

The famed investor's company also exited Merck and trimmed several holdings including Visa, Mastercard, and AbbVie.

Warren Buffett's Berkshire Hathaway reveals new bets on Floor & Decor and Royalty Pharma

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2021 Results - Earning Call Transcript

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q3 Earnings and Revenue Estimates

RPRX buys royalties of high-profile assets.

News for Royalty Pharma Stock (RPRX)